Karachi: Citi Pharma Limited has formally announced the submission of a non-binding offer for the potential acquisition of a significant pharmaceutical company in Pakistan. The announcement was made in accordance with Section 96 of the Securities Act, 2015, and Clause 5.6.1 of the Pakistan Stock Exchange (PSX) Rule Book.

The non-binding offer marks a strategic move by Citi Pharma Limited as part of its expansion plans to solidify its position as one of the leading players in the Pakistani pharmaceutical industry. The company aims to enhance its market footprint through this potential acquisition, which could significantly increase its market share in the competitive sector.

According to information available from the Pakistan Stock Exchange (PSX), the submission of the offer is an initial step in a process that will involve a thorough due diligence examination. This due diligence is crucial to ensure that the acquisition aligns with Citi Pharma's strategic goals and regulatory compliance. Any further developments regarding this acquisition will depend on the outcomes of this process and will require approval from the company's Board of Directors and the relevant regulatory authorities.

Citi Pharma Limited has reiterated its commitment to maintaining transparency and keeping the Exchange and its shareholders apprised of any substantial developments. This acquisition, if successful, could potentially redefine the pharmaceutical landscape in Pakistan, positioning Citi Pharma as a major entity in the market category.